Prilenia inks agreement with Ferrer to commercialize and co─develop pridopidine in Europe and other select markets
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), announced that it has …